IBD Pathophysiology Flashcards

1
Q

Describe the epidemiology of Crohn’s disease: Prevalence, geography, sex, age

A

Prevalence: 26-200/100k (Rising)
Higher prevalence in Northern lattitudes
Even F:M ratio
Dx between 15-30 with another peak in 50-60s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe the epidemiology of Ulcerative Colitis: geography, prevalence, age of onset, sex

A

North-south gradient
Rates of UC are stable
Age of onset similar
Even incidence between sexes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the function of NOD2. What is its significance

A

NOD2 recognizes bacterial MDP and binds peptidoglycans. It then up regulates NF-kB and MAPK signaling to modulate inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is evidence for the role of microbiome in IBD? (4)

A

IBD does not occur in germ-free environment
Some pts with CD develop Ab to enteric flora proteins
Most common locations of CD are ileum/colon, where bacteria levels are highest
Abx appear to have potential benefit for some

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which immune cell types are involved in IBD?

A

There is dysregulation of both Th1 and Th2- mediated response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which environmental factors are related to IBD? (4)

A

High SES
Dietary factors
Smoking: increases risk of CD; protective in UC
Stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are goals of therapy in IBD?

A

Improvement in QOL, induce remission, avoid surgery, mucosal healing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which forms of IBD are “curable”?

A

UC can be cured with colectomy. Crohn’s is not curable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What factors warrant more aggressive early therapy? (5)

A

Tobacco use (for Crohn’s)
Perianal or penetrating disease
Requirement for steroids
Age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are recommended therapies for mild disease? (4)

A

Short course of glucocorticoids for initial induction of remission
5-ASAs for UC
Budesonide for CD
Topical steroids for distal disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are recommend therapies for moderate to severe disease?

A

Immunomodulators: thiopurine antimetabolites and methotrexate
Biologics: anti-TNF, anti-alpha4, anti-cell signaling molecules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are different preparations of melamine that have been developed? (4)

A

pH dependent systems
Diazo-bonded systems with bacterial release
Osalazine (double 5-ASAs)
Belsalazide (inert carrier)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is MOA of ASAs?

A

Anti-inflammatory==>inhibition of T cell proliferation, antigen presentation, leukocyte adhesion, decreased TNF production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is use for ASAs? What are AEs? (2)

A

Beneficial in UC, not in Crohn’s.

AEs: Paradoxical diarrhea, interstitial nephritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is clinical use for glucocorticoids in IBD?

A

Mainstay in induction of remission, but not useful in maintenance of remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are AE associated with glucocorticoid use? (long list)

A

Neuropsychiatric, Cushingoid, myopathy, glucose intolerance, infection, wound healing, hirsutism, bon effects, hypertension

17
Q

What is budesonide? What are the reasons for its use?

A

Novel steroid compound with ileal or colonic release formulations.

High degree of first-pass lessens system side effects
Standard initial therapy

18
Q

What is MOA of immunomodulators?

A

Both azathioprine and 6MP inhibit DNA synthesis

19
Q

What is role of TPMT polymorphism in azathioprine/6MP?

A

1/300 have a reduced TPMT activity==>shunts AZA/6MP to an active metabolite 6-TGN, which markedly increases side effects

20
Q

Describe the use and efficacy for thiopurines

A

Induction and maintenance of remission of CD

Reduces steroid utilization

21
Q

What are AE of thiopurines? (5)

A
Leukopenia/marrow suppression
Pancreatitis
Drug-induced hepatitis 
Infection
Malignancy
22
Q

What is mechanism of methotrexate?

Described its efficacy

A

Folate antagonist that carriers anti-inflammatory properties

It’s effective in induction/maintenance of remission in Crohn’s; being evaluated for UC

23
Q

What are AE of methotrexate? (6)

A
Nausea
Hepatic fibrosis
Teratogenic
Marrow suppression
Infection
Pneumonitis
24
Q

What is mechanism of anti-TNF therapy?

A

Bind soluble/cell-bound TNF-a and inhibit.
Induce apoptosis of T cells and lymphocytes in lamina propria
Alter cyotkine secretion in serum

25
What is approved use for anti-TNF therapy?
Induction and maintenance of remission in Crohn's and UC
26
What are AE for anti-TNF therapy? (4)
Transfusion reactions or delayed hypersensitivity reactons Drug-induced lupus Infection Malignancy
27
What is the use for anti-alpha4 inhibitors?
Natalizumab-- benefit for MS also induction and maintenance of remission in Crohn's
28
What is major risk of natalizumab? How is it managed?
Increased risk of progressive multifocal leukoencephalopathy. Screen for JC virus
29
What is advantage of vedolizumab?
No PML risk Approved for use in both CD/UC